期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 12, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13045-019-0736-3
关键词
Small cell lung cancer; Chemotherapy; Immunotherapy; Targeted therapy
资金
- Medical Science and Technology Foundation of Henan Province [201601026]
- National Natural Science Foundation of China [81272600]
- Henan Provincial Training Abroad Foundation for Leaders of Medical Science [201082]
- Henan Provincial Special Funds for Health and Technological Innovative Talents [2011020155]
- Henan Provincial Research Program of Application Foundation and Advanced Technology [112300410033]
- Henan Province
- Ministry of Health of Medical Science and Technology Program [201601026]
- 51282 project Leading Talent of Henan Provincial Health Science and Technology Innovation Talents [[2016]32]
- Wu Jieping Medical Foundation [320.6799.15018]
- Program for Science and Technology Innovation Talents in Universities of Henan Province [18HASTIT044]
Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据